European Mapping of Axial Spondyloarthritis (EMAS) Survey

Professor Marco Garrido Cumbrera, University of Seville, Spain led this exciting project with assistance from ASIF and Novartis Pharma AG.

The aim of EMAS was to bring together patients, patient organisations, medial experts and researchers from 13 European countries to generate patient-relevant, scientific evidence on the management and impact of axSpA.

Key issues and opportunities that the survey identified are:

  • Despite improvements, diagnostic delay is still too long;
  • Active disease and psychological distress in diagnosed patients highlight key areas of opportunity for optimizing care;
  • Active disease limits quality of life and professional opportunities;
  • Patients are concerned about the future of their disease

Co-creating solutions with all stakeholders will improve quality of life and standard of care for axSpA patients.

Two abstracts were presented at ACR and an introduction to the survey at the SpA congress in Ghent in 2018.  Those posters can be found below.

EMAS Poster_ICS_FINAL
ACR DD.
ACR Psych Distress.

We will bring you more results from the survey over the coming months.

Phase 2 is now underway across the globe with the International Mapping of Axial Spondyloarthritis (IMAS) survey.

EMAS is an expansion of the Atlas of Axial Spondyloarthritis in Spain, an initiative led by Professor Marco Garrido Cumbrera and the University of Seville, Spain and in partnership with Ceade and Novarti Farmacéutica

 

Other Projects

World AS Day

This year World AS Day is on Saturday 4 May. Read More

Global Spondyloarthritis Summit 2019 – Now Open for Registration

Registration is now open for SAA's first-ever Global Spondyloarthritis Summit, Friday, May 3rd

Read More